Peripheral Arterial Disease
Conditions
Brief summary
This registry is created under the sponsorship of the Outpatient Endovascular and Interventional Society (OEIS) to monitor the clinical course and treatment outcomes of patients undergoing office-based endovascular procedures.
Interventions
None listed
Sponsors
Syntactx
Outpatient Endovascular and Interventional Society
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is 18 years of age or older; * Patient is identified as having undergone a percutaneous transluminal vascular intervention or attempted intervention, in an ambulatory (outpatient) facility, for the treatment of peripheral vascular disease within native arteries or bypass grafts, from the infrarenal aorta distally to the feet.
Exclusion criteria
* Patient treated for a non-eligible condition or procedure * Diagnostic procedures without intervention or attempted interventions * Serious mental illness that might preclude subject's ability to comply with follow up * Life expectancy of less than 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antiplatelet Therapy (ACC/AHA/PAD Coalition) | 30 days | To collect the clinical variables of Patients undergoing endovascular procedures in an outpatient angiograPercentage of patients with PAD that have been prescribed an antiplatelet medication at the reported encounter. |
| Preventive Care and Screening: Tobacco Use | 30 days | Screening and Cessation Intervention. Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. |
| Lipid-Lowering Medications for Patients with PAD | 30 days | The rate at which patients with documented peripheral artery disease have documentation of a currently prescribed antihyperlipidemic medication treatment. This may include one of the following: Statin, Bile acid sequestrants, Niacin, Ezetemibe, Fibrates, PCSK9 Inhibitors |
| Optimal vascular care | 30 days | This measure is a composite score of appropriate vascular care measures for treatment of PAD. This measure is a composite result of 1: Antiplatelet Therapy; 2: Preventive Care and Screening: Tobacco Use; and 3: Lipid-Lowering Medications (Statin) for Patients with PAD |
| Preventive Care and Screening: Influenza Immunization. | 30 days | — |
| Pneumonia Vaccination Status for Older Adults. | 30 days | — |
| Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented. | 30 days | — |
| Appropriate non-invasive arterial testing for patients with intermittent claudication who are undergoing a lower extremity peripheral vascular intervention. | 30 days | Proportion of patients with non-invasive evaluations present/available prior to lower extremity peripheral vascular interventions in patients with intermittent claudication. |
| Appropriate non-invasive arterial testing for patients with critical limb ischemia who are undergoing a LE peripheral vascular intervention. | 30 days | Proportion of patients with non-invasive evaluations present/available prior to LE peripheral vascular interventions in patients with critical limb ischemia. |
| Emergent transfer from an outpatient, ambulatory surgical center, or office setting. | 30 days | Rate of emergent transfer from an outpatient, ASC, or office setting to an acute care facility as a result of an invasive peripheral vascular intervention. |
Countries
United States
Contacts
Primary ContactDhru Bhatt
Backup ContactElizabeth Ouriel
Outcome results
None listed